Our Company
McNeil Pediatrics™ can trace its origins to the storefront pharmacy that Robert McNeil opened in the Kensington section of Philadelphia in 1879. There, McNeil manufactured and sold high-quality medications that quickly won the professional endorsement of doctors and hospitals throughout the city. In the early 20th century, the business shifted away from retail operators and into the expanding pharmaceutical market. In 1933, the drug store was incorporated as McNeil Laboratories Inc., which specialized in the direct marketing of prescription pharmaceuticals to doctors and hospitals. In1959, McNeil Laboratories was acquired by Johnson & Johnson. The company continued to thrive through the next four decades, building a leadership position in its markets.
Today, McNeil Pediatrics™ is a leader in Attention Deficit Hyperactivity Disorder (ADHD) treatment for children, adolescents and adults with its drug CONCERTA®, (methylphenidate HCl), an extended release, once-a-day treatment featuring the OROS® delivery system. The CONCERTA® brand, which was the first 12-hour extended-release methylphenidate (MPH) treatment for ADHD, is the market leader for MPH treatment of children and adolescents with ADHD.
OROS® is a registered trademark of Alza Corporation.
CONCERTA® is a prescription product approved for the treatment of attention deficit hyperactivity disorder (ADHD) as part of a total treatment program that may include counseling or other therapies.
IMPORTANT SAFETY INFORMATION
Talk to your healthcare professional for a proper diagnosis and treatment of ADHD. Only a healthcare professional can decide whether medication is right for you or your child.
CONCERTA® should not be taken by patients who have: allergies to methylphenidate or other ingredients in CONCERTA®; significant anxiety, tension, or agitation; glaucoma; tics, Tourette's syndrome, or family history of Tourette's syndrome; current or past use of monoamine oxidase inhibitor (MAOI); esophagus, stomach, or intestinal narrowing. Children under six years of age should not take CONCERTA®.
Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if you or your child has had problems with alcohol or drugs; has had any heart problems, heart defects, high blood pressure, or a family history of these problems; has had depression, abnormal thoughts or visions, bipolar disorder, or seizure. Contact your healthcare professional immediately if you or your child: develops abnormal thinking or hallucinations, abnormal or extreme moods and/or excessive activity; or if aggressive behavior or hostility develops or worsens while taking CONCERTA®. Your child's healthcare professional should check height and weight often and may interrupt CONCERTA® treatment if your child is not growing or gaining weight as expected.
Stimulants may impair the ability of the patient to operate potentially hazardous machinery or vehicles. Caution should be used accordingly until you are reasonably certain that CONCERTA® does not adversely affect your ability to engage in such activities.
The most common adverse reaction (>5%) reported in children and adolescents was upper abdominal pain. The most common adverse reactions (>10%) reported in adults were dry mouth, nausea, decreased appetite, headache, and insomnia.
See full U.S. Prescribing Information and Medication Guide for CONCERTA®.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
